Nasdaq GlobeNewswire

This is a test release from GlobeNewswire

Del

This is my test document. (Bold)

Entry paragraph. Lorem ipsum dolor sit amLorem ipsum dolor sit amLorem ipsum dolor sit amLorem ipsum dolor sit amLorem ipsum dolor sit amLorem ipsum dolor sit amLorem ipsum dolor sit amLorem ipsum dolor sit amLorem ipsum dolor sit amLorem ipsum dolor sit amLorem ipsum dolor sit amLorem ipsum dolor sit am.

This is another bold line of text. Another bold line of text.

Paragraph one. Lorem ipsum dolor sit amet, ex populo deleniti deseruisse quo, et his prima tractatos urbanitas, sit reque possit ne. An timeam vituperata ius, ex dicta tacimates hendrerit pro. In eam possit delectus, eos et volutpat consequuntur. Mel an impetus volutpat disputationi. At voluptua hendrerit mel.

Paragraph two. Te tantas dicunt interesset pri. Primis comprehensam an eos, ad nam gubergren accommodare. Laudem maluisset scripserit sea id, vel menandri liberavisse mediocritatem eu. Cu sit justo persequeris. Duo quis percipit sapientem ei, quod deseruisse temporibus ad his. Qui in putant assueverit. At ornatus delenit mel, usu errem mandamus cu, has ne paulo sonet inermis. Debitis efficiendi ne quo. Ut mel partem malorum adversarium, per malis legere dissentiunt no. Ut mei ferri instructior, mei ne viderer mediocritatem, ne vero ullum mei.

Paragraph three. Eum ea fugit maiestatis. Ne eum affert doctus, quo ad alterum concludaturque. Usu habemus alienum ei, meliore detracto sadipscing ut qui, ex comprehensam s.

Bullets (italic)

  • This is a bullet point. Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro
  • Another bullet point. Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro
    • This is an indented bullet point. Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro
    • Another indented bullet point. Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro Ei debet minimum duo, eam at amet intel
      • 3 level indented bullet point. egam reprehendunt. Ius ne dicta appetere, populo doming feugait pro
      • 3 level indented bullet point. Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro
      • 3 level indented bullet point.Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro

Numbered lists (underlined)

  1. This is a bullet point #1. Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro
  2. This is bullet point #2. Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro
    1. This is indented bullet point #1. Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro
    2. This is indened bullet point #2. Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro Ei debet minimum duo, eam at amet intel

                                                               i.      Far right indented bullet point letter "i" - egam reprehendunt.

  1. This is a bullet point #1. Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro
  2. This is a bullet point #2. Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro

Numbered list (bold, italic, underlined)

  1. This is a bullet point #1.  Ei debet minimum duo, eam at amet intellegam reprehendunt. Ius ne dicta appetere, populo doming feugait pro

Hyperlink

Financial Table:

    Three Months Ended   Six Months Ended
(In thousands, except per share data)   June 30, 2014   March 31, 2014   June 30, 2013   June 30, 2014   June 30, 2013
Net income   $ 38,541     $ 34,500     $ 34,307     $ 73,041     $ 66,359  
Less: Preferred stock dividends and discount accretion   1,581     1,581     2,617     3,162     5,233  
Net income applicable to common shares—Basic   36,960     32,919     31,690     69,879     61,126  
Add: Dividends on convertible preferred stock, if dilutive   1,581     1,581     2,581     3,162     5,162  
Net income applicable to common shares—Diluted   38,541     34,500     34,271     73,041     66,288  
Weighted average common shares outstanding   46,520     46,195     37,486     46,358     37,231  
Effect of dilutive potential common shares:                              
Common stock equivalents   1,327     1,434     7,334     1,381     7,343  
Convertible preferred stock, if dilutive   3,075     3,075     5,020     3,075     5,020  
Weighted average common shares and effect of dilutive potential common shares   50,922     50,704     49,840     50,814     49,594  
Net income per common share:                              
Basic   $ 0.79     $ 0.71     $ 0.85     $ 1.51     $ 1.64  
Diluted   $ 0.76     $ 0.68     $ 0.69     $ 1.44     $ 1.34  

ö, ä, ü, €, Æ, Ø, ©, ®, ™, β, £,"', «», ², Å, ï, ô, ù, €, á, é, è, í, ó, ú, Ñ, ¿ ? ! {} [] () + - !@#$%^&*

CONTACT INFORMATION:
Contact Name: Lucia Olaso Escoriaza
Contact Title: Media Relations
Phone Number: +44 00000 000
Email Address: lucia.olasoescoriaza@nasdaq.com

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer20.11.2017 13:00Pressemelding

ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status Approval supported by robust data from a randomized, well-controlled Phase 3 trial Only PARPi to offer once-daily, oral dosing to enable convenient administration for maintenance treatment First commercial launches planned for Germany and the UK this December ZUG, Switzerland, Nov. 20, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology focused biopharmaceutical company, announced today that the European Commission (EC) has granted marketing authorization for ZEJULA® (niraparib) as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response (CR) or partial response (PR) to platinum-based chemotherapy. ZEJULA is the first once-daily, oral poly (

PledPharma and Solasia enter license agreement to develop and commercialize PledOx® in Asia20.11.2017 07:30Pressemelding

Stockholm, 2017-11-20 07:30 CET (GLOBE NEWSWIRE) -- Stockholm, Sweden / Tokyo, Japan, November 20th 2017 - PledPharma AB (“PledPharma”) (STO: PLED) and Solasia Pharma K.K. (“Solasia”) (TSE: 4597) today jointly announce that they have entered a license agreement pertaining to the clinical development and commercialization of PledOx® in Japan, China, Hong Kong, Macau, South Korea and Taiwan. Under the terms of this agreement, PledPharma grants exclusive development and commercialization rights to PledOx® in the territories mentioned and Solasia will pay upfront, development, regulatory and sales milestones of up to ~USD 83 million (SEK 700 million)*. In addition, Solasia will pay industry standard royalty rates on sales applicable for a deal pertaining to an in-licensed asset in Phase III development. Solasia will also fully finance an expansion of the Phase III program to include Asian patients subject to regulatory consultations. The license agreement is initially focused on th

CrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology Research17.11.2017 18:07Pressemelding

SANTA CLARA, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the launch of a grant program supporting oncology research scientists which provides funding for projects that show promise for scientific advancement of Patient Derived Xenograft (PDX) technology. Research Grants up to $50,000 will be awarded to projects focused on accelerating the pace of preclinical innovation and novel PDX methodologies that improve clinical predictions with sound science. The program offers an opportunity for investigators to receive funding for projects that may not receive support through traditional funding channels. Submitted proposals will be reviewed and selected by CrownBio's Scientific Steering Committee with the goa

Barings Backs Sentinel Capital Partners in Acquisition of Nekoosa17.11.2017 17:00Pressemelding

CHARLOTTE, N.C., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Barings, one of the world's leading asset management firms, announced today that it served as Lead Agent on a senior secured credit facility to support Sentinel Capital Partners in its acquisition of Nekoosa ("Nekoosa" or the "Company"). Headquartered in Nekoosa, Wisconsin, the Company is a leading manufacturer of specialty paper and film products used in the graphics and commercial print markets, including application and pressure-sensitive tapes, specialty synthetic papers, sheeted digital and offset grade carbonless paper, and extruded film products. Nekoosa serves a highly diverse base of more than 70,000 commercial print and graphics shops in 65 countries. Barings served as lead senior lender on the transaction, which included a senior term loan and a revolving credit facility. "Sentinel is pleased to have Barings' support on our investment in Nekoosa," said Scott Perry, a partner with Sentinel Capital Partner

At SC17, ExaScaler and PEZY Computing Unveil Gyoukou Supercomputer with a High Combined Green500/Top500 Ranking16.11.2017 23:29Pressemelding

ExaScaler and PEZY Computing Also Take Top Three Green500 Positions DENVER, Nov. 16, 2017 (GLOBE NEWSWIRE) -- At SC17, ExaScaler and PEZY Computing unveiled their Gyoukou supercomputer whose Green500 and Top500 rankings attest to a unique combination of high efficiency and computing power. The Gyoukou supercomputer is installed at the Yokohama Research Institute in Japan. (Video: PEZY Liquid immersion cooling) PEZY supercomputers leverage 48V Factorized Power, a high efficiency, high density power distribution architecture. PEZY's CPUs are co-packaged with Vicor's Power-on-Package ("PoP") Modular Current Multipliers ("MCMs"), which enable efficient, direct 48V to sub-1V current multiplication at the XPU. ExaScaler and PEZY Computing also achieved the #1, #2 and #3 positions on the Green500. These supercomputer system installations also utilize 48V Factorized Power. Come see us at SC17 at Booth 633 where ExaScaler / PEZY Computing will be

ELS Educational Services, Inc. Launches New Vacation English Program Starting January 201816.11.2017 20:59Pressemelding

New York, New York, Nov. 16, 2017 (GLOBE NEWSWIRE) -- ELS Educational Services, Inc. - one of the leading language services providers worldwide - has launched a new vacation English language program, ELS Language Experience+, which is set to begin enrollment for January 2018. "Here at ELS, our students and their English language goals always come first, and we are proud to introduce ELS Language Experience+ as an exciting new addition to the many quality programs we offer them," said ELS Chief Operating Officer, Reiji Terasaka. "This conversation-oriented, flexible new vacation English program allows students to make the most of their English instruction while gaining an invaluable cultural experience at the same time." ELS Language Experience+ concentrates on everyday speaking, communication skills and discussion, within a flexible course structure (three or six hours of study per day). Courses offered include: Everyday English, Grammar in Action, D

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom